Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001437749-26-001671·Framework Ventures IV L.P.
Schedule 13D ownership disclosure
NovaBay Pharmaceuticals Inc
Common Stock, $0.01 par value · CUSIP: 66987P409
Event date: 2026-01-16
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Framework Ventures IV L.P.Reported CIK 0002028474
Shares: 56,806,080.00 · Class: 45.0%
- Framework Ventures Management LLCReported CIK 0002091751
Shares: 56,806,080.00 · Class: 45.0%
- Framework Ventures IV GP LLCReported CIK 0002092591
Shares: 56,806,080.00 · Class: 45.0%
- Spencer VanceReported CIK 0002092030
Shares: 56,806,080.00 · Class: 45.0%
- Anderson Michael ErnestReported CIK 0002093174
Shares: 56,806,080.00 · Class: 45.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001437749-26-001671
- Form type
- SCHEDULE 13D/A
- Filer
- Framework Ventures IV L.P.
- CIK
- CIK 2028474
- Filed
- Jan 21, 2026
- Reporting period
- Jan 16, 2026
- Description
- Schedule 13D beneficial ownership